Related Experiment Video
Updated: Dec 28, 2025
12:03
Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
Published on: June 7, 2016
18.3K
Angiotensin II for the emergency physician
Marianne C Wallis1, Jonathan H Chow2, Michael E Winters3
1Division of Pulmonary and Critical Care, University of Maryland School of Medicine, Baltimore, Maryland, USA Mariannewallis@gmail.com.
Emergency Medicine Journal : EMJ
|February 21, 2020
Summary
Refractory hypotension is a critical challenge in emergency medicine. This review explores synthetic angiotensin II (Ang-2) as a vasopressor, detailing its mechanisms, effects, and clinical potential for undifferentiated shock.
Area of Science:
- Critical care medicine
- Pharmacology
- Emergency medicine
Background:
- Refractory hypotension presents significant challenges for acute care clinicians, especially emergency physicians managing undifferentiated shock.
- Angiotensin II (Ang-2) has a history as a vasopressor, with renewed interest following recent regulatory approvals for synthetic formulations.
Purpose of the Study:
- To review the discovery and development of Angiotensin II (Ang-2).
- To discuss the complex vasoconstriction mechanisms of Ang-2.
- To evaluate the potential adverse effects and clinical utility of Ang-2 for emergency physicians.
Main Methods:
- A comprehensive literature search was conducted.
- Existing research on Angiotensin II (Ang-2) was synthesized.
- Clinical applications and pharmacological data were analyzed.
Main Results:
- Angiotensin II (Ang-2) exhibits complex vasoconstriction pathways.
- Recent regulatory approvals (FDA 2017, EMA 2019) support its clinical feasibility.
- Potential adverse effects require careful consideration.
Conclusions:
- Angiotensin II (Ang-2) represents a promising vasopressor option for refractory hypotension in undifferentiated shock.
- Understanding its mechanisms and risks is crucial for effective emergency physician application.
- Further clinical research may solidify its role in acute care settings.
Related Concept Videos
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
2.2K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.2K
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
2.3K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.3K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
832
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
832
01:25Antihypertensive Drugs: Direct Renin Inhibitors
1.2K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.2K
01:29Heart Failure II: Pathophysiology
603
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
603
01:29Hypertension II: Pathophysiology
635
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
635